Synthesis and blood glucose lowering effect of novel pyridazinone substituted benzenesulfonylurea derivatives

European Journal of Medicinal Chemistry

Volumn 44, Issue 6, 2009, Pages 2673-2678

  Rathish, I G ^a   Javed, Kalim ^a   Bano, Sameena ^a   Ahmad, Shamim ^a   Alam, M S ^a   Pillai, K K ^b  

^a HAMDARD UNIVERSITY   (India)

^b HAMDARD UNIVERSITY   (India)

Author keywords

Blood glucose lowering effect; Carbamate; Pyridazinone; Sulfonylurea

Indexed keywords

1 [4 (6 PHENYL 3 OXOPYRIDAZIN 2 YL)BENZENESULFONYL] 3 (1 BUTYL)UREA; 1 [4 (6 PHENYL 3 OXOPYRIDAZIN 2 YL)BENZENESULFONYL] 3 (1 PROPYL)UREA; 1 [4 (6 PHENYL 3 OXOPYRIDAZIN 2 YL)BENZENESULFONYL] 3 (BENZYL)UREA; 1 [4 (6 PHENYL 3 OXOPYRIDAZIN 2 YL)BENZENESULFONYL] 3 (CYCLOHEXYL)UREA; 1 [4 [6 (4 CHLORO 3 METHYLPHENYL) 3 OXOPYRIDAZIN 2 YL]BENZENESULFONYL] 3 (CYCLOHEXYL)UREA; 1 [4 [6 (4 CHLOROPHENYL) 3 OXOPYRIDAZIN 2 YL]BENZENESULFONYL] 3 (1 BUTYL)UREA; 1 [4 [6 (4 CHLOROPHENYL) 3 OXOPYRIDAZIN 2 YL]BENZENESULFONYL] 3 (1 PROPYL)UREA; 1 [4 [6 (4 CHLOROPHENYL) 3 OXOPYRIDAZIN 2 YL]BENZENESULFONYL] 3 (BENZYL)UREA; 1 [4 [6 (4 CHLOROPHENYL) 3 OXOPYRIDAZIN 2 YL]BENZENESULFONYL] 3 (CYCLOHEXYL)UREA; 1 [4 [6 (4 METHOXYPHENYL) 3 OXOPYRIDAZIN 2 YL]BENZENESULFONYL] 3 (1 BUTYL)UREA; 1 [4 [6 (4 METHOXYPHENYL) 3 OXOPYRIDAZIN 2 YL]BENZENESULFONYL] 3 (CYCLOHEXYL)UREA; 1 [4 [6 (4 METHYLPHENYL) 3 OXOPYRIDAZIN 2 YL]BENZENESULFONYL] 3 (1 BUTYL)UREA; 1 [4 [6 (4 METHYLPHENYL) 3 OXOPYRIDAZIN 2 YL]BENZENESULFONYL] 3 (1 PROPYL)UREA; 1 [4 [6 (4 METHYLPHENYL) 3 OXOPYRIDAZIN 2 YL]BENZENESULFONYL] 3 (BENZYL)UREA; 1 [4 [6 (4 METHYLPHENYL) 3 OXOPYRIDAZIN 2 YL]BENZENESULFONYL] 3 (CYCLOHEXYL)UREA; BENZENESULFONYLUREA DERIVATIVE; CARBAMIC ACID DERIVATIVE; GLICLAZIDE; PYRIDAZINONE DERIVATIVE; SULFONAMIDE; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD GLUCOSE MONITORING; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; INFRARED SPECTROSCOPY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; FEMALE; GLUCOSE TOLERANCE TEST; HYPOGLYCEMIC AGENTS; MALE; MOLECULAR STRUCTURE; PYRIDAZINES; RATS; RATS, WISTAR; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONYLUREA COMPOUNDS;

EID: 64249126686     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2008.12.013     Document Type: Article

References (13)

1. Sakurai H. Chem. Rec. 2 (2002) 237-248
2. World Health Organization (WHO). Diabetes mellitus. Report of a WHO study group. WHO Technical Report Series (TRS) 727. WHO, Geneva, 1985, pp. 7-98.
3. Dvornik D. In: Porte D. (Ed). Aldose reductase inhibition: an approach to the prevention of diabetic complications (1987), McGraw Hill, New York 221-323
4. Dvornik D. In: Porte D. (Ed). Aldose reductase inhibition: an approach to the prevention of diabetic complications (1987), McGraw Hill, New York 69-151
5. Kinoshita J.H., and Nishimura C. Diabetes Metab. Rev. 4 (1988) 323-337
6. DeFronzo R.A. Ann. Intern. Med. 133 (1999) 281-303
7. Kecskemeti V., Bagi Z., Posa I., Koesis E., and Koltai M.I. Curr. Med. Chem. 9 (2002) 53-71
8. Coudert P., Duroux E., Bastide P., and Couquelet J. J. Pharm. Belg. 46 (1991) 375-380
9. Costantino L., Rastelli G., Vescovini K., Cignarella G., Vianello P., Corso A.D., Cappiello M., Mura U., and Barlocco D. J. Med. Chem. 36 (1996) 4396-4405
10. Costantino L., Rastelli G., Cignarella G., and Barlocco D. Farmaco 55 (2000) 544-552
11. I.G. Rathish, Ph.D. thesis, Jamia Hamdard, New Delhi, India, 2008.
12. Weir G.C., Clore E.T., Zmachinski C.J., and Bonner-Weir S. Diabetes 30 (1981) 590-595
13. Rorsman P. Diabetologia 40 (1997) 487-495